Figure 3. Cross-Resistance to Protease Inhibitors After Virologic Failure with Indinavir or Nelfinavir

This study involved 225 patients who had HIV RNA greater than 2,000 copies/ml while receiving highly active antiretroviral therapy with 2 nucleoside reverse transcriptase inhibitors and one protease inhibitor. The results are presented based on prior virologic failure (greater than 4-fold phenotypic resistance) with indinavir or nelfinavir. The results show phenotypic susceptibility to 5 different protease inhibitors, with reduced phenotypic susceptibility defined as a greater than 4-fold increase in the 50% inhibitory concentration compared with drug-sensitive virus. This figure is based on data from Cohen CJ, Hunt S, Sension M, et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS. 2002;16:579-88.

[Close Window]